Meglumine antimoniate

Section: 6. Anti-infective medicines > 6.5. Antiprotozoal medicines > 6.5.2. Antileishmaniasis medicines

EMLc | ATC codes: P01CB01

Indication	Cutaneous leishmaniasis ICD11 code: 1F54.1
Medicine type	Chemical agent
List type	Core
Formulations	**Parenteral > General injections > IM:** 1.5 g per 5 mL in 5 mL ampoule
EML status history	First added in 1987 (TRS 770) Changed in 1989 (TRS 796) Changed in 2002 (TRS 914) Changed in 2007 (TRS 950) Changed in 2009 (TRS 958) Changed in 2023 (TRS 1049)
Sex	All
Age	Also recommended for children
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more about patents.
Wikipedia	Meglumine antimoniate
DrugBank	Meglumine antimoniate (Pentavalent Antimony)

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the listing for sodium stibogluconate / meglumine antimoniate on the EML and EMLc be amended to list each medicine separately with updated dosage form descriptions as follows: Sodium stibogluconate: Injection: 100 mg/mL in 30 mL vial Meglumine antimoniate: Injection: 1.5 g/5 mL in 5 mL ampoule